KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Capital Expenditures (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Capital Expenditures data on record, last reported at -$200000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 100.94% year-over-year to -$200000.0; the TTM value through Dec 2025 reached $1.6 million, down 93.01%, while the annual FY2025 figure was $1.6 million, 93.01% down from the prior year.
  • Capital Expenditures reached -$200000.0 in Q4 2025 per EBS's latest filing, up from -$4.7 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $90.6 million in Q2 2021 and bottomed at -$102.5 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $5.3 million, with a median of $4.8 million recorded in 2024.
  • The widest YoY moves for Capital Expenditures: up 182.83% in 2022, down 13700.0% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at -$600000.0 in 2021, then plummeted by 13700.0% to -$82.8 million in 2022, then skyrocketed by 113.77% to $11.4 million in 2023, then soared by 86.84% to $21.3 million in 2024, then crashed by 100.94% to -$200000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$200000.0 in Q4 2025, -$4.7 million in Q3 2025, and $5.0 million in Q2 2025.